---
title: "Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑"
id: "plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl"
canonical_url: "https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "PLOS Medicine"
source_url: "https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012"
published_at: "2026-11-03T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Cardiovascular risk and mortality after statin initiation: achieved LDL and non‑HDL levels in a 3‑
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-medicine-0-risk-of-cardiovascular-events-and-mortality-associated-with-ldl-and-non-hdl
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** PLOS Medicine
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012)
- **Published At:** 2026-11-03T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators analysed electronic health records from Hong Kong, New Zealand and the UK to identify 185,237 adults who initiated **statin** therapy for primary prevention and had lipid measurement within two years. - The cohort excluded patients with prior atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease; follow-up extended to 2017 in the original datasets and varied by region. - Lipid categories at two years: for **LDL** cholesterol, <1.4, 1.4–1.7, 1.8–2.5, and ≥2.6 mmol/L; distributions showed most patients in the 1.8–2.5 and ≥2.6 mmol/L bands. - Multivariable Cox regression models adjusted for age, sex, multiple comorbidities (including diabetes and hypertension), psychiatric and rheumatologic conditions, smoking/alcohol misuse, and concomitant cardio‑active medications. - Lower achieved **LDL** and **non‑HDL** cholesterol were associated with reduced hazard of major adverse cardiovascular events (**MACE**) versus higher concentrations; pooled HRs reported for several category comparisons. - Continuous analyses indicated an approximately log‑linear association between achieved lipids and **MACE** in Hong Kong and the UK; New Zealand estimates were more variable and imprecise at very low concentrations. - After adjustment, very low **LDL** (<1.4 mmol/L) and very low **non‑HDL** were not clearly associated with increased all‑cause mortality; point estimates were near null and CIs crossed unity. - Authors noted heterogeneity across cohorts, possible confounding by indication due to treatment intensity guided by baseline cardiovascular risk, residual confounding from comorbidities and lifestyle interventions, and that estimates are conditional on surviving to the lipid test and being tested. - The study supports achieving guideline targets (non‑HDL <3.4 mmol/L; LDL <2.6 mmol/L) within two years of statin start for primary prevention but acknowledges imprecision at the lowest lipid levels and cohort differences. - Data access statements and regional data sources were reported; individual‑level linked data are not publicly shareable because of privacy protections.
## Clinical Analysis & Structured Key Points
[ Skip to main content ](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#main-content) Advertisement * [plos.org](https://plos.org/) * [Create account](https://community.plos.org/registration/new) * [Sign in](https://journals.plos.org/user/secure/login?page=%2Fplosmedicine%2Farticle%3Fid%3D10.1371%2Fjournal.pmed.1005012) * * About * Browse * Publish * [](https://journals.plos.org/plosmedicine/ "PLOS Medicine") * Search [advanced search](https://journals.plos.org/plosmedicine/search) * 0 [Save](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#savedHeader) [Total Mendeley and Citeulike bookmarks.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#savedHeader) * 0 [Citation](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#citedHeader) [Paper's citation count computed by Dimensions.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#citedHeader) * 27 [View](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#viewedHeader) [PLOS views and downloads.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#viewedHeader) * 0 [Share](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#discussedHeader) [Sum of Facebook, Twitter, Reddit and Wikipedia activity.](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012#discussedHeader) Open Access Peer-reviewed Research Article # Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study * Joseph Edgar Blais , Roles Conceptualization, Formal analysis, Funding acquisition, Project administration, Visualization, Writing – original draft, Writing – review & editing * E-mail: joeblais@hku.hk ¶☯ These authors contributed equally to this work and are both considered first authors. Affiliation Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-7895-198X ](https://orcid.org/0000-0001-7895-198X "ORCID Registry") ⨯ * Ralph Kwame Akyea , Roles Conceptualization, Formal analysis, Funding acquisition, Project administration, Visualization, Writing – review & editing ¶☯ These authors contributed equally to this work and are both considered first authors. Affiliation Precision Healthcare and Drug Safety (PRISM) Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0003-4529-8237 ](https://orcid.org/0000-0003-4529-8237 "ORCID Registry") ⨯ * William Harrison, Roles Formal analysis, Writing – review & editing Affiliation Medicines Intelligence Research Group, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0009-0006-3848-265X ](https://orcid.org/0009-0006-3848-265X "ORCID Registry") ⨯ * Amy Hai Yan Chan, Roles Conceptualization, Supervision, Writing – review & editing Affiliation Medicines Intelligence Research Group, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-1291-3902 ](https://orcid.org/0000-0002-1291-3902 "ORCID Registry") ⨯ * Wenfang Zhong, Roles Formal analysis, Visualization, Writing – review & editing Affiliation Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-7343-094X ](https://orcid.org/0000-0001-7343-094X "ORCID Registry") ⨯ * Stephen Franklin Weng, Roles Conceptualization, Funding acquisition, Supervision Affiliation GSK R&D Global Headquarters, London, United Kingdom ⨯ * Kebede Abera Beyene, Roles Conceptualization, Writing – review & editing Affiliation Medicines Intelligence Research Group, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-1057-2593 ](https://orcid.org/0000-0002-1057-2593 "ORCID Registry") ⨯ * Wallis C. Y. Lau, Roles Conceptualization, Writing – review & editing Affiliations Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom, Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0003-2320-0470 ](https://orcid.org/0000-0003-2320-0470 "ORCID Registry") ⨯ * Kenneth K. C. Man, Roles Conceptualization, Writing – review & editing Affiliations Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom, Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, United Kingdom [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-8645-1942 ](https://orcid.org/0000-0001-8645-1942 "ORCID Registry") ⨯ * Nadeem Qureshi, Roles Conceptualization, Writing – review & editing Affiliation Precision Healthcare and Drug Safety (PRISM) Research Group, Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, United Kingdom [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0003-4909-0644 ](https://orcid.org/0000-0003-4909-0644 "ORCID Registry") ⨯ * Esther Wai Yin Chan, Roles Resources, Supervision, Writing – review & editing Affiliations Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, Accident and Emergency Department, Queen Mary Hospital, Pok Fu Lam, Hong Kong SAR, China, The University of Hong Kong Shenzhen Institute of Research and Innovation, Shenzhen, China [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0002-7602-9470 ](https://orcid.org/0000-0002-7602-9470 "ORCID Registry") ⨯ * Ian Chi Kei Wong, Roles Funding acquisition, Resources, Supervision, Writing – review & editing Affiliations Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China, Macau University of Science and Technology, Macau SAR, China, Aston Centre of Excellence in Pharmacotherapy Optimisation and Pharmacoepidemiology Research, Aston Pharmacy School, Aston University, Birmingham, United Kingdom [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-8242-0014 ](https://orcid.org/0000-0001-8242-0014 "ORCID Registry") ⨯ * Jeff Harrison Roles Formal analysis, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing Affiliation Medicines Intelligence Research Group, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand [ ![ORCID logo](https://journals.plos.org/resource/img/orcid_16x16.png) https://orcid.org/0000-0001-8478-7469 ](https://orcid.org/0000-0001-8478-7469 "ORCID Registry") ⨯ # Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study * Joseph Edgar Blais, * Ralph Kwame Akyea, * William Harrison, * Amy Hai Yan Chan, * Wenfang Zhong, * Stephen Franklin Weng, … * Kebede Abera Beyene, * Wallis C. Y. Lau, * Kenneth K. C. Man, * Nadeem Qureshi ![PLOS](https://journals.plos.org/resource/img/logo-plos-full-color.svg) x * Published: November 3, 2026 * * [Article](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012) * [Authors](https://journals.plos.org/plosmedicine/article/authors?id=10.1371/journal.pmed.1005012) * [Metrics](https://journals.plos.org/plosmedicine/article/metrics?id=10.1371/journal.pmed.1005012) * [Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005012) * [Media Coverage](http://plos.altmetric.com/details/doi/10.1371/journal.pmed.1005012) * [Abstract](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#abstract0) * [Author summary](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#abstract1) * [Introduction](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#sec007) * [Methods](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#sec008) * [Results](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#sec017) * [Discussion](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#sec021) * [Supporting information](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#sec022) * [Acknowledgments](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#ack) * [References](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012#references) * [Reader Comments](https://journals.plos.org/plosmedicine/article/comments?id=10.1371/journal.pmed.1005012) * [Figures](https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005012) [?](https://journals.plos.org/plosmedicine/s/accepted-manuscripts#loc-early-version) ## This is an uncorrected proof. ## Abstract ### Background The cardiovascular and mortality benefits of achieving guideline-recommended concentrations of low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol with statins in primary prevention remain uncertain. ### Methods and findings In this new-user cohort study, we used electronic healthcare databases from Hong Kong (HK), New Zealand (NZ) and the United Kingdom (UK) to identify 185,237 patients initiating statins between 1 January 2007 and 31 December 2012 (with follow-up to 31 December 2017) without atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. Associations between LDL and non-HDL cholesterol measured within 2 years post-initiation with the outcomes of major adverse cardiovascular events (MACE) or all-cause mortality were assessed in landmark analyses using multivariable Cox regression adjusted for age, sex, hypertension, atrial fibrillation, diabetes mellitus, dyslipidaemia, obesity, smoking, alcohol misuse, rheumatoid arthritis, systemic lupus erythematosus and connective tissue disorders, severe mental illness, antihypertensive drugs, antidiabetic drugs, antiplatelet drugs, and anticoagulant drugs. Estimates were pooled using random-effects meta-analysis. At 2 years, LDL cholesterol was ). This study is based in part on data from the Clinical Practice Research Datalink (CPRD) obtained under licence from the UK Medicines and Healthcare products Regulatory Agency. Requests to access CPRD data are reviewed via the CPRD Research Data Governance process to ensure that the proposed research is of benefit to patients and public health. Additional information is available on the CPRD website: . New Zealand national health collections data (National Minimum Dataset, Pharmaceutical Collection, Mortality Register, and Primary Health Organisation National Enrolment Service) are held by Te Whatu Ora – Health New Zealand. Researchers seeking access to these data may apply through the Health New Zealand data access process ( ). The linked regional laboratory dataset covering Auckland and Northland was obtained via TestSafe ( ). Access t
## Related Clinical Research

- [Comparing BMI, Waist Circumference, and BRI for Predicting ASCVD, AF, and Mortality in 1.2M Koreans](https://medichelpline.com/clinical-feed/plos-one-14-prognostic-associations-of-anthropometric-indices-with-major-health-outcomes-a.md)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)
- [CXCL10 rs8878 genotype associates with preserved T cells and 30‑day survival in sepsis](https://medichelpline.com/clinical-feed/frontiers-in-immunology-1-cxcl10-rs8878-identifies-a-genotype-associated-immune-phenotype-linked-to-t.md)
- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [ZEUS trial: IL-6 blocker ziltivekimab lowered inflammation but did not cut major CV events](https://medichelpline.com/clinical-feed/aha-news-1-researchers-say-inflammation-as-a-treatment-target-still-important-despite.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.